Psychemedics logo

Psychemedics(OTC) PMD

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1992)-32%
5 Year-68%
1 Year+18%
1 Month+0%
N/A
Psychemedics last closing stock price
MetricPriceDate
Last closeUSD 2.492026-09-25
Psychemedics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 2.492026-09-11
1 month+0%USD 2.492026-07-23
3 month+0%USD 2.492026-06-26
Year to date+55.63%USD 1.602025-12-31
1 year+17.79%USD 2.112025-09-25
3 year-33.6%USD 3.752023-09-26
5 year-68.27%USD 7.852021-09-24
Since inception-31.87%USD 3.651992-06-15

Psychemedics Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$19.69M

Net Income (TTM)

-$1.86M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Nov 10, 2025

PMD News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Psychemedics

Psychemedics Corporation, established in 1986 and based in Acton, Massachusetts, specializes in comprehensive drug abuse detection services. The company utilizes hair sample analysis to identify a wide range of substances, serving clients across the United States and internationally.

Products and Services
  • Hair sample analysis for drug abuse detection
  • Testing for a broad spectrum of substances, including opioids and synthetic drugs
  • Quantitative data on drug consumption patterns over time
Growth Outlook
  • Recent quarterly revenue of $4.43 million shows potential for recovery
  • Gross profit margin improved to 31.37% in Q4 2024
  • Expansion into international markets may drive future growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of $20.5 million
  • Net income of $189,000 reported in Q4 2024, indicating a positive trend
  • Current ratio of 1.82 suggests strong short-term financial health
Psychemedics Corporation operates in the medical diagnostics and research sector, focusing on drug testing services that are increasingly relevant in today's society. The company's innovative approach to drug detection through hair analysis not only identifies substance use but also provides historical data, making it a valuable tool for employers, law enforcement, and treatment professionals. The recent financial performance indicates a potential turnaround, with a notable increase in revenue and improvements in gross profit margins. The company's ability to adapt and expand into new markets may further enhance its growth prospects. With a solid foundation and a commitment to quality, Psychemedics Corporation presents an intriguing opportunity for investors interested in the healthcare and diagnostics industry.
AI Generated • Sep 24, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

101

CEO

Brian Hullinger

Website

www.psychemedics.com

Headquarters

Acton, MA 01720, US

PMD Financials

Key Financial Metrics (TTM)

Gross Margin

36.07%

Operating Margin

-9.62%

Net Income Margin

-9.45%

Return on Equity

-31.54%

Return on Capital

-30.07%

Return on Assets

-22.37%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$7.10M

Operating Income

-$1.89M

EBITDA

$191.00K

Operating Cash Flow

$929.00K

Capital Expenditure

-$56.00K

Free Cash Flow

$873.00K

Cash & ST Invst.

$1.42M

Total Debt

$1.17M

Psychemedics Performance Analysis

Psychemedics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 24,909,000N/A
20222022-12-31USD 25,240,0001.3%
20232023-12-31USD 22,098,000-12.4%
20242024-12-31USD 19,685,000-10.9%
Psychemedics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-317.2%
Q22024-06-30-11.7%
Q32024-09-309.5%
Q42024-12-31-14.5%
Psychemedics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.12N/A
20222022-12-31USD -0.1960.9%
20232023-12-31USD -0.72275.6%
20242024-12-31USD -0.32-56.2%
Psychemedics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q12024-03-3125.0%
Q22024-06-30-16.7%
Q32024-09-3035.1%
Q42024-12-31135.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2024YOY CHG

Revenue

$4.43M

-11.5%

Gross Profit

$1.39M

-32.6%

Gross Margin

31.37%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

116

N/A

Net Income

$189.00K

+120.0%

EBITDA

$584.00K

+299.3%

Quarterly Fundamentals

Name
Q4 2024YOY CHG

Total Cash

$1.42M

-27.9%

Total Debt

$1.17M

-49.3%

Accounts Receivable

$2.52M

-31.9%

Inventory

$0.00

N/A

Long Term Debt

$477.00K

-49.5%

Short Term Debt

$689.00K

-71.3%

Return on Assets

-22.37%

N/A

Return on Invested Capital

-33.76%

N/A

Free Cash Flow

$993.00K

+48.9%

Operating Cash Flow

$1.02M

+53.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CEMIChembio Diagnostics, Inc.
$0.46+0.22%
TMDITitan Medical Inc.
$0.14+0.00%
WENAAnew Medical, Inc.
$0.73-3.84%
TLPHTalphera, Inc.
$1.07-0.93%

Trending Stocks

Symbol / CompanyPricePrice Chg
CIFRCipher Digital
$11.34-12.77%
BMBLBumble
$5.95+56.58%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$37.42+0.62%
INTCIntel
$102.81+1.44%

Questions About PMD

What is the current price of Psychemedics?

Psychemedics is trading at N/A per share.

What is the 52-week range for Psychemedics?

Over the past 52 weeks, Psychemedics has traded between N/A and N/A.

How much debt does Psychemedics have?

As of the most recent reporting period, Psychemedics reported total debt of $1.17M.

How much cash does Psychemedics have on hand?

Psychemedics reported $1.42M in cash and cash equivalents in its most recent financial results.

What is Psychemedics’s dividend yield?

Psychemedics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services